CGON

Cg Oncology Inc

64.68

Oct 30 • 3:59 PM ET +1.21 (1.91%)

64.68

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NASD

Peers: IBRX URGN ENGN TARA AURA CADL JNJ REPL TLX IOVA

| Held by: VTI VB IWM XBI VBK VXF IWO VTWO IBB SCHA

Scroll to Statements

Index	RUT
Market Cap	5.73B
Enterprise Value	4.71B
Income	-224.38M
Sales	6.23M
Book/sh	11.65
Cash/sh	11.60
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	142
IPO	Jan 25, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	920.27
P/B	5.55
P/C	5.58
P/FCF	-
EV/EBITDA	-
EV/Sales	756.63
Quick Ratio	22.20
Current Ratio	22.22
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-2.70
EPS next Y	-3.13
EPS next Q	-0.83
EPS this Y	-59.51%
EPS next Y	5.64%
EPS next 5Y	24.33%
EPS past 3/5Y	-46.89% -65.75%
Sales past 3/5Y	176.56% -20.97%
EPS Y/Y TTM	-60.33%
Sales Y/Y TTM	1030.31%
EPS Q/Q	-64.91%
Sales Q/Q	-
Earnings	Aug 06 BMO
EPS/Sales Surpr.	-35.50% 220.68%

Insider Own	33.33%
Insider Trans	1.13%
Inst Own	89.41%
Inst Trans	2.58%
ROA	-25.11%
ROE	-26.41%
ROIC	-21.64%
Gross Margin	-93.32%
Oper. Margin	-4056.18%
Profit Margin	-3602.68%
SMA20	3.00%
SMA50	-6.85%
SMA200	-1.86%
Trades

Shs Outstand	88.31M
Shs Float	59.09M
Short Float	15.02%
Short Ratio	10.29
Short Interest	8.87M
52W High	80.97 -20.12%
52W Low	35.80 80.67%
Volatility	5.01% 4.34%
ATR (14)	2.87
RSI (14)	49.12
Beta	0.30
Rel Volume	1.01
Avg Volume	862.28K
Volume	869,953

Perf Week	4.81%
Perf Month	-5.37%
Perf Quarter	-6.46%
Perf Half Y	-2.40%
Perf YTD	55.78%
Perf Year	52.30%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.13
Target Price	91.08
Prev Close	63.47
Price	64.68
Change %	1.91%

Consensus

Strong Buy

Avg. Price Target

$91.08

Implied Upside

+40.8%

Analysts16incl. previous ratings

Rating Distribution14 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
May 19, 2026	Initiated	WWolfe Research	Peer Perform
Dec 11, 2025	Initiated	WWedbush	Outperform	$70	+8.2%
Nov 24, 2025	Initiated	TTruist	Buy
Oct 08, 2025	Initiated	GGuggenheim	Buy	$90	+39.1%
Aug 19, 2025	Initiated	PPiper Sandler	Overweight	$55	-15.0%
Jul 10, 2025	Resumed	GGoldman	Buy	$40	-38.2%
May 02, 2025	Initiated	JJP Morgan	Overweight	$41	-36.6%
Apr 16, 2025	Initiated	BScotiabank	Sector Perform	$23	-64.4%
Jan 07, 2025	Initiated	TTD Cowen	Buy
Oct 24, 2024	Initiated	UUBS	Buy	$60	-7.2%
Sep 23, 2024	Initiated	RRBC Capital Mkts	Outperform	$66	+2.0%
Aug 28, 2024	Initiated	RROTH MKM	Buy	$65	+0.5%
Jun 28, 2024	Initiated	BBofA Securities	Buy	$65	+0.5%
Feb 20, 2024	Initiated	MMorgan Stanley	Overweight	$55	-15.0%
Feb 20, 2024	Initiated	GGoldman	Neutral	$42	-35.1%
Feb 20, 2024	Initiated	CCantor Fitzgerald	Overweight	$75	+16.0%
Feb 14, 2024	Initiated	HH.C. Wainwright	Buy	$75	+16.0%

Oct-13-26 08:00AM	CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer (GlobeNewswire)
Sep-11-26 11:35AM	3 Stocks Call Traders Are Targeting Today (Schaeffer's Research)
Sep-02-26 08:00AM	CG Oncology to Present at Upcoming Investor Conferences in September (GlobeNewswire)
Aug-06-26 08:15AM	CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-27-26 06:45PM	CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology (GlobeNewswire) +6.06%
04:05PM	Loading…
May-28-26 04:05PM	CG Oncology to Present at Upcoming Investor Conferences in June (GlobeNewswire)
May-19-26 08:00AM	SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award (GlobeNewswire)
May-15-26 08:00AM	CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients (GlobeNewswire)
May-11-26 04:15PM	CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC (GlobeNewswire)
May-08-26 08:30AM	CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
May-05-26 08:00AM	CG Oncology to Present at Upcoming Investor Conferences in May (GlobeNewswire)
Mar-08-26 03:02AM	CG Oncology Conference: Credo Posts 75.5% CR in BOND-003, BLA Filing Targeted for 2026 (MarketBeat)
Mar-06-26 10:22AM	H.C. Wainwright Raises its Price Target on CG Oncology, Inc. (CGON) to $80 and Maintains a Buy Rating (Insider Monkey)
Mar-02-26 09:27AM	Company News for Mar 2, 2026 (Zacks)
Feb-27-26 08:30AM	CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates (GlobeNewswire)
08:00AM	Loading…
Feb-23-26 08:00AM	CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Jan-15-26 10:26AM	CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why (Zacks)
Jan-12-26 10:35AM	Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 (PR Newswire)
Jan-09-26 08:30AM	CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC (GlobeNewswire) +29.26%
Jan-06-26 08:00AM	CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-25 08:00AM	SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award (GlobeNewswire)
Dec-09-25 12:20AM	CG Oncology, Inc. (CGON) is a Buy on Cancer Treatment Development: Truist Securities (Insider Monkey)
Dec-05-25 08:30AM	New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Nov-26-25 07:00AM	CG Oncology Announces New Board Member and Board Transition (GlobeNewswire)
Nov-25-25 04:05PM	CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting (GlobeNewswire)
Nov-17-25 09:26AM	Company News for Nov 17, 2025 (Zacks)
Nov-14-25 09:10AM	CG Oncology, Inc. (CGON) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +8.61%
08:00AM	CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-06-25 08:10AM	ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Oct-17-25 09:55PM	CG Oncology (CGON) Gets Initiated With a Buy at Guggenheim (Insider Monkey) +5.14%
04:33PM	Loading…
Oct-16-25 04:33PM	Guggenheim Initiates CG Oncology (CGON) Coverage with $90 PT, Highlights Bladder Cancer Therapeutic Cretostimogene (Insider Monkey)
Oct-08-25 06:14PM	Why Cg Oncology Stock Rocketed 7% Higher Today (Motley Fool) +7.13% +9.21%
Sep-22-25 03:19AM	CG Oncology (CGON) PT Raised to $79 by Morgan Stanley on Strong Clinical Pipeline for Bladder Cancer Treatment (Insider Monkey)
Sep-19-25 09:20AM	Strength Seen in Intellia Therapeutics (NTLA): Can Its 29.8% Jump Turn into More Strength? (Zacks)
Sep-18-25 10:03AM	CG Oncology, Inc. (CGON) Moves 5.5% Higher: Will This Strength Last? (Zacks)
Sep-08-25 09:30AM	Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market (PR Newswire)
Sep-05-25 07:00AM	CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months (GlobeNewswire) +6.88%
Sep-03-25 08:00AM	CG Oncology Completes Enrollment in PIVOT-006 (GlobeNewswire)
Aug-29-25 08:00AM	CG Oncology's Executive Leadership to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-20-25 12:14AM	CG Oncology's Bladder Cancer Drug Shows Strong Clinical Data, Drives Optimism Despite Price Target Cut (Insider Monkey)
12:13AM	H.C. Wainwright Reiterates a Buy on CG Oncology (CGON), Keeps the PT (Insider Monkey)
Aug-08-25 08:00AM	CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-06-25 08:40AM	Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates (Zacks) -6.12%
Jul-31-25 11:58AM	CG Oncology, Inc. (CGON) Reports 75.5% Complete Response in Bladder Cancer Trial (Insider Monkey)
Jul-29-25 04:05PM	Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals (GlobeNewswire)
Jul-07-25 08:30AM	Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs (PR Newswire)
Jul-06-25 04:15AM	Morgan Stanley Lifts PT on CG Oncology (CGON) to $56, Keeps an Overweight Rating (Insider Monkey)
Jul-01-25 02:30PM	Lustgarten Foundation Appoints Arthur Kuan, MS, to Board of Directors (PR Newswire)
Jun-18-25 11:19AM	Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going (PR Newswire)
Jun-05-25 08:00AM	CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-22-25 08:46AM	CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success (Zacks)
May-15-25 08:00AM	CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-14-25 09:38AM	Company News for May 14, 2025 (Zacks)
May-13-25 09:10AM	CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
07:45AM	Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-01-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
10:01AM	CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
08:00AM	SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award (GlobeNewswire)
Apr-29-25 09:10AM	CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains? (Zacks)
02:02AM	Why CG Oncology, Inc. (CGON) Surged on Monday (Insider Monkey)
Apr-28-25 04:05PM	CG Oncology Soars On Its Johnson & Johnson-Rivaling Cancer Drug (Investor's Business Daily) +25.03%
11:14AM	CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why (Benzinga)
10:24AM	CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug (Investor's Business Daily)
Apr-26-25 04:10PM	CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting (GlobeNewswire)
Apr-24-25 08:00AM	CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025 (GlobeNewswire)
Apr-11-25 05:30AM	How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs (The Wall Street Journal) +9.36%
Apr-02-25 12:32PM	CG Oncology Looks Attractive At Current Prices (Rating Upgrade) (Seeking Alpha)
Mar-31-25 09:55AM	Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade (Zacks) -7.31%
08:00AM	CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates (GlobeNewswire)
05:54AM	Company News for Mar 31, 2025 (Zacks)
Mar-28-25 07:00AM	CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates (GlobeNewswire)
Mar-26-25 05:45PM	Is CG Oncology (CGON) Among the Best IPO Stocks to Buy in 2025? (Insider Monkey)
Mar-24-25 08:00AM	Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy (GlobeNewswire) +5.47%
Mar-12-25 08:00AM	CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates (GlobeNewswire)
Feb-26-25 08:00AM	CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-25-25 09:49AM	Is CG Oncology, Inc. (CGON) An Oversold Biotech Stock to Buy Now? (Insider Monkey) -6.65%
Feb-23-25 01:29PM	Why CG Oncology, Inc. (CGON) is the Most Oversold Pharma Stock to Buy According to Analysts (Insider Monkey)
Feb-20-25 12:19PM	Why CG Oncology (CGON) Is the Most Oversold Healthcare Stock to Buy Now (Insider Monkey)
Jan-16-25 09:55AM	Does CG Oncology, Inc. (CGON) Have the Potential to Rally 123.34% as Wall Street Analysts Expect? (Zacks)
Jan-03-25 10:00AM	How to Navigate the Stock and Bond Markets in 2025 (The Wall Street Journal) +5.35%
Dec-16-24 04:05PM	CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Dec-12-24 08:19PM	CG Oncology Announces Pricing of Public Offering (GlobeNewswire) -9.01%
Dec-11-24 06:17AM	CG Oncology Announces Proposed Public Offering (GlobeNewswire) -5.85%
Dec-06-24 08:00AM	SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award (GlobeNewswire)
07:10AM	CG Oncology announces data from Phase 3 BOND-003 trial (TipRanks)
Dec-05-24 11:35AM	CG Oncology Touts Encouraging Data From Late-Stage Study Of Bladder Cancer Candidate (Benzinga) -6.54%
07:00AM	Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Dec-02-24 08:00AM	CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024 (GlobeNewswire)
Nov-20-24 08:00AM	CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting (GlobeNewswire)
Nov-12-24 08:00AM	CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -6.83%
Nov-11-24 08:00AM	CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer (GlobeNewswire)
Sep-14-24 05:25PM	Cg Oncology Inc. (CGON): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
Aug-30-24 08:00AM	CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-08-24 08:23AM	CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +7.02%
Jun-18-24 08:00AM	CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec (GlobeNewswire)
Jun-06-24 12:14PM	CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC (GlobeNewswire)
May-24-24 08:00AM	CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting (GlobeNewswire) +9.07%
May-11-24 10:16AM	ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 01:54PM	CGON Stock Earnings: CG Oncology Misses EPS for Q1 2024 (InvestorPlace) -7.43%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
POST LEONARD E	Director	Oct 15 '26	Option Exercise	0.60	1,000	600	1,000	Oct 19 04:30 PM
POST LEONARD E	Director	Oct 15 '26	Sale	62.06	1,000	62,065	0	Oct 19 04:30 PM
LEONARD POST	Director	Oct 15 '26	Proposed Sale	61.84	3,000	185,520		Oct 15 04:41 PM
AMBAW BELLETE	Officer	Sep 21 '26	Proposed Sale	76.01	30,787	2,340,024		Sep 21 04:04 PM
AMBAW BELLETE	Officer	Sep 17 '26	Proposed Sale	76.50	6,532	499,698		Sep 17 04:33 PM
POST LEONARD E	Director	Sep 15 '26	Option Exercise	0.60	1,000	600	1,000	Sep 17 04:30 PM
POST LEONARD E	Director	Sep 15 '26	Sale	72.98	1,000	72,980	0	Sep 17 04:30 PM
AMBAW BELLETE	Officer	Sep 11 '26	Proposed Sale	75.00	826	61,950		Sep 11 05:10 PM
AMBAW BELLETE	Officer	Sep 02 '26	Proposed Sale	77.61	29,630	2,299,448		Sep 02 05:02 PM
AMBAW BELLETE	Officer	Aug 31 '26	Proposed Sale	75.50	50,000	3,775,250		Aug 31 04:50 PM
AMBAW BELLETE	Officer	Aug 27 '26	Proposed Sale	79.39	5,789	459,561		Aug 27 05:07 PM
AMBAW BELLETE	Officer	Aug 25 '26	Proposed Sale	79.55	10,551	839,338		Aug 25 04:38 PM
AMBAW BELLETE	Officer	Aug 24 '26	Proposed Sale	79.52	5,762	458,185		Aug 24 05:12 PM
AMBAW BELLETE	Officer	Aug 19 '26	Proposed Sale	79.54	100,000	7,954,105		Aug 19 04:05 PM
POST LEONARD E	Director	Aug 14 '26	Option Exercise	0.60	1,000	600	1,000	Aug 18 04:30 PM
POST LEONARD E	Director	Aug 14 '26	Sale	74.54	1,000	74,540	0	Aug 18 04:30 PM
AMBAW BELLETE	Officer	Aug 17 '26	Proposed Sale	76.95	52,438	4,034,894		Aug 17 04:09 PM
AMBAW BELLETE	Officer	Aug 14 '26	Proposed Sale	75.02	19,364	1,452,635		Aug 14 07:00 PM
AMBAW BELLETE	Officer	Aug 13 '26	Proposed Sale	75.95	25,989	1,973,971		Aug 13 05:07 PM
AMBAW BELLETE	Officer	Aug 12 '26	Proposed Sale	78.62	32,137	2,526,515		Aug 12 05:43 PM
AMBAW BELLETE	Officer	Aug 11 '26	Proposed Sale	76.21	50,000	3,810,255		Aug 11 06:05 PM
AMBAW BELLETE	Officer	Aug 10 '26	Proposed Sale	75.41	50,000	3,770,580		Aug 10 04:03 PM
AMBAW BELLETE	Officer	Aug 07 '26	Proposed Sale	75.25	9,250	696,062		Aug 07 04:39 PM
AMBAW BELLETE	Officer	Aug 06 '26	Proposed Sale	75.63	75,000	5,672,212		Aug 06 04:16 PM
AMBAW BELLETE	Officer	Aug 05 '26	Proposed Sale	73.50	25,000	1,837,500		Aug 05 04:32 PM
AMBAW BELLETE	Officer	Jul 29 '26	Proposed Sale	73.50	4,303	316,270		Jul 29 04:29 PM
AMBAW BELLETE	Officer	Jul 28 '26	Proposed Sale	72.50	50,000	3,625,195		Jul 28 04:58 PM
AMBAW BELLETE	Officer	Jul 27 '26	Proposed Sale	72.56	50,000	3,627,995		Jul 27 04:02 PM
AMBAW BELLETE	Officer	Jul 23 '26	Proposed Sale	71.77	50,000	3,588,620		Jul 23 04:02 PM
POST LEONARD E	Director	Jul 15 '26	Option Exercise	0.60	1,000	600	1,000	Jul 17 04:15 PM
POST LEONARD E	Director	Jul 15 '26	Sale	71.17	1,000	71,170	0	Jul 17 04:15 PM
AMBAW BELLETE	Officer	Jul 15 '26	Proposed Sale	72.77	52,438	3,816,008		Jul 15 04:24 PM
Mulay James	Director	Jul 10 '26	Option Exercise	26.63	24,165	643,514	24,165	Jul 14 04:15 PM
Mulay James	Director	Jul 10 '26	Sale	75.16	24,165	1,816,241	0	Jul 14 04:15 PM
JAMES MULAY	Director	Jul 10 '26	Proposed Sale	73.32	20,237	1,483,777		Jul 10 04:41 PM
JAMES MULAY	Director	Jul 01 '26	Proposed Sale	71.05	3,928	279,084		Jul 01 05:06 PM
Liu Brian Guan-Chyun	Director	Jun 25 '26	Buy	66.87	371,085	24,814,454	1,886,236	Jun 29 05:26 PM
POST LEONARD E	Director	Jun 24 '26	Option Exercise	0.60	5,000	3,000	5,000	Jun 25 04:30 PM
POST LEONARD E	Director	Jun 24 '26	Sale	70.00	5,000	350,000	0	Jun 25 04:30 PM
LEONARD POST	Director	Jun 24 '26	Proposed Sale	65.73	5,000	328,650		Jun 24 04:37 PM
POST LEONARD E	Director	Jun 22 '26	Option Exercise	0.60	5,000	3,000	5,000	Jun 23 04:30 PM
POST LEONARD E	Director	Jun 22 '26	Sale	65.00	5,000	325,000	0	Jun 23 04:30 PM
LEONARD POST	Director	Jun 22 '26	Proposed Sale	61.08	6,000	366,480		Jun 22 04:49 PM
Mulay James	Director	Jun 15 '26	Option Exercise	9.64	1,964	18,926	1,310	Jun 16 05:07 PM
Mulay James	Director	Jun 15 '26	Sale	60.12	1,964	118,076	0	Jun 16 05:07 PM
POST LEONARD E	Director	Jun 04 '26	Option Exercise	0.60	1,000	600	1,000	Jun 05 04:30 PM
POST LEONARD E	Director	Jun 04 '26	Sale	54.50	1,000	54,500	0	Jun 05 04:30 PM
LEONARD E POST	Director	Jun 04 '26	Proposed Sale	54.42	3,000	163,260		Jun 04 04:29 PM
Mulay James	Director	Apr 17 '26	Option Exercise	36.63	15,600	571,428	15,600	Apr 20 04:15 PM
Mulay James	Director	Apr 17 '26	Sale	73.01	15,600	1,138,956	0	Apr 20 04:15 PM
JAMES MULE	Director	Apr 17 '26	Proposed Sale	66.34	17,564	1,165,196		Apr 17 04:34 PM
Mulay James	Director	Mar 16 '26	Option Exercise	9.64	1,964	18,926	1,310	Mar 17 04:15 PM
Mulay James	Director	Mar 16 '26	Sale	63.50	1,964	124,714	0	Mar 17 04:15 PM
Kuan Arthur	Chief Executive Officer	Mar 12 '26	Option Exercise	1.72	64,612	111,133	200,763	Mar 13 04:09 PM
Kuan Arthur	Chief Executive Officer	Mar 04 '26	Option Exercise	1.72	102,871	176,938	139,022	Mar 06 05:52 PM
Mulay James	Director	Jan 09 '26	Option Exercise	12.07	11,145	134,515	10,491	Jan 13 04:15 PM
Mulay James	Director	Jan 09 '26	Sale	52.47	11,145	584,799	0	Jan 13 04:15 PM
JAMES MULAY	Director	Jan 09 '26	Proposed Sale	41.93	13,109	549,660		Jan 09 04:32 PM
POST LEONARD E	Director	Nov 17 '25	Option Exercise	0.60	1,000	600	1,000	Nov 18 04:30 PM
POST LEONARD E	Director	Nov 17 '25	Sale	41.43	1,000	41,430	0	Nov 18 04:30 PM

CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul A. DeRidder on September 24, 2010 and is headquartered in Dallas, TX.

PresidentMr. Arthur Kuan

Chief Financial OfficerMr. James M. DeTore

General CounselMr. Joshua F. Patterson

Chief Medical OfficerDr. Vijay Kasturi M.D.

Chief Technical OfficerMr. Swapnil Bhargava Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CGON

Cg Oncology Inc

Upgrade your Finviz experience